Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

23.3%

7 terminated/withdrawn out of 30 trials

Success Rate

63.2%

-23.3% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

42%

5 of 12 completed trials have results

Key Signals

6 recruiting5 with results5 withdrawn

Enrollment Performance

Analytics

Phase 2

13(48.1%)

Phase 1

11(40.7%)

N/A

3(11.1%)

27Total

Phase 2(13)

Phase 1(11)

N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (30)

Showing 20 of 30 trials

NCT06941857Phase 2Recruiting

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Role: collaborator

NCT06015659Phase 2Active Not Recruiting

ZN-c3 + Gemcitabine in Pancreatic Cancer

Role: collaborator

NCT05014776Phase 2Completed

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Role: collaborator

NCT05077800Phase 2Active Not Recruiting

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Role: collaborator

NCT07199764Phase 2Recruiting

Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer

Role: collaborator

NCT02110498Completed

Early Detection of Pancreatic Cystic Neoplasms

Role: collaborator

NCT01202136Completed

The Clinical,Radiologic,Pathologic and Molecular Marker Characteristics of Pancreatic Cysts Study

Role: collaborator

NCT05419479Phase 1Suspended

Switch Maintenance in Pancreatic

Role: collaborator

NCT06782932Phase 1Recruiting

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Role: collaborator

NCT03762590Not ApplicableActive Not Recruiting

GENetic Education Risk Assessment and TEsting Study

Role: collaborator

NCT03563248Phase 2Active Not Recruiting

Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Role: collaborator

NCT05132244Not ApplicableRecruiting

Monitoring and Managing Glucose Levels in People With Pancreatic Cancer

Role: collaborator

NCT06747845Phase 2Recruiting

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

Role: collaborator

NCT02754726Phase 2Completed

Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Role: collaborator

NCT03697564Phase 2Completed

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

Role: collaborator

NCT06707896Phase 1Withdrawn

TCR1020-CD8 T Cells in KRAS-mutated Cancers

Role: collaborator

NCT06252545Not ApplicableRecruiting

Promoting CT Engagement for Pancreatic Cancer With App

Role: collaborator

NCT03520790Phase 1Terminated

Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer

Role: collaborator

NCT04916236Phase 1Terminated

Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

Role: collaborator

NCT03415854Phase 2Completed

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

Role: collaborator